Clinical Trials · NCT07797036
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
- Phase
- Phase 2/Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- University of Massachusetts, Worcester
- Enrollment
- 226
- Start date
- Sep 2027
- Locations
- 1 site, United States
- Primary endpoint
- Metabolic Syndrome